Myriad Genetics Plunges to 5-Year Low as Forecast Falls Short

  • Company cites weakness in genetic testing for cancer risk
  • Shares decline 34% to lowest level since December 2011

Myriad Genetics Inc. plunged the most in 16 years after the company forecast 2017 sales and earnings that fell substantially short of analysts’ estimates, due largely to declining revenue from tests used to detect a genetic risk of developing cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.